Compounds > gefitinib
Page last updated: 2024-09-03

gefitinib and Pleural Effusion, Malignant

gefitinib has been researched along with Pleural Effusion, Malignant in 17 studies

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (29.41)29.6817
2010's11 (64.71)24.3611
2020's1 (5.88)2.80

Authors

AuthorsStudies
Jiang, Y; Li, D; Li, Y; Liao, X; Liu, N; Qin, D; Tang, J; Wang, Y; Yin, T; Yu, M1
Clément-Duchêne, C; Lamaze, R; Martinez, L1
Avila Martínez, RJ; Hernández Voth, A; Villena Garrido, V1
Chu, NM; Feng, AC; Hsu, LH; Kao, SH; Liu, KJ; Tsai, MF; Wu, CR1
Lai, FC; Li, X; Lin, JB; Lin, JW; Lin, M; Liu, B; Luo, RG; Qiu, ML; Tu, YR1
Hsiue, EH; Lee, JH; Lin, CC; Yang, JC1
Abe, H; Aikawa, E; Akiba, J; Azuma, K; Kage, M; Kawahara, A; Nakashima, K; Sumi, A; Taira, T; Takamori, S; Yamaguchi, T1
Fukuoka, J; Isa, S; Kawaguchi, T; Kitaichi, M; Koh, Y; Kubo, A; Kusunoki, Y; Nakagawa, K; Okamoto, I; Takada, M1
Chang, YL; Jan, IS; Luo, SC; Shih, JY; Su, KY; Tsai, TH; Wu, SG; Yang, PC; Yu, CJ; Yu, SL1
Chua, KT; Lai, NL; Lee, CH; Liam, CK; Lim, BK; Pang, YK1
Chang, YL; Chen, YH; Kuo, YW; Shih, JY; Tsai, MF; Wu, SG; Yang, CH; Yang, PC; Yu, CJ1
Jan, IS; Liao, WY; Shih, JY; Tsai, MF; Wu, SG; Yang, CH; Yang, PC; Yu, CJ1
Hsu, HS; Huang, BS; Huang, MJ; Lim, KH; Tzen, CY; Yen, Y1
Goto, H; Matsumori, Y; Nakataki, E; Ryan, AJ; Sone, S; Wedge, SR; Yano, S1
Aoe, K; Aoe, M; Asano, H; Date, H; Hiraki, A; Ichihara, S; Katayama, H; Kiura, K; Sano, Y; Shimizu, N; Soh, J; Sugi, K; Toyooka, S1
Fujiwara, Y; Kasahara, K; Kimura, H; Kunitoh, H; Nishio, K; Sone, T; Tamura, T1
Aoe, M; Date, H; Ichihara, S; Ito, S; Kiura, K; Kobayashi, N; Sano, Y; Soh, J; Suehisa, H; Toyooka, S; Yamane, M1

Reviews

1 review(s) available for gefitinib and Pleural Effusion, Malignant

ArticleYear
Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer.
    Expert review of molecular diagnostics, 2016, Volume: 16, Issue:12

    Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pleural Effusion, Malignant; Protein Kinase Inhibitors; Quinazolines; Reagent Kits, Diagnostic; Real-Time Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Analysis, DNA

2016

Trials

1 trial(s) available for gefitinib and Pleural Effusion, Malignant

ArticleYear
Sequential treatment strategy for malignant pleural effusion in non-small cell lung cancer with the activated epithelial grow factor receptor mutation.
    Journal of drug targeting, 2017, Volume: 25, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Paclitaxel; Pleural Effusion, Malignant; Quinazolines

2017

Other Studies

15 other study(ies) available for gefitinib and Pleural Effusion, Malignant

ArticleYear
Progression of malignant pleural effusion during the early stage of gefitinib treatment in advanced EGFR-mutant lung adenocarcinoma involving complex driver gene mutations.
    Signal transduction and targeted therapy, 2020, 05-27, Volume: 5, Issue:1

    Topics: Adenocarcinoma of Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Proteins; Pleural Effusion, Malignant; Retrospective Studies

2020
[Primary lateral sclerosis and lung adenocarcinoma].
    Revue des maladies respiratoires, 2013, Volume: 30, Issue:3

    Topics: Adenocarcinoma; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Causality; Diagnosis, Differential; Dysarthria; Electromyography; Fatal Outcome; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Motor Neuron Disease; Motor Neurons; Multimodal Imaging; Paraneoplastic Syndromes, Nervous System; Pemetrexed; Pleural Effusion, Malignant; Positron-Emission Tomography; Quadriplegia; Quinazolines; Tomography, X-Ray Computed

2013
Spontaneous hemothorax as a presenting form of bronchogenic carcinoma.
    Archivos de bronconeumologia, 2013, Volume: 49, Issue:10

    Topics: Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Large Cell; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Hemothorax; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Pleural Effusion, Malignant; Pulmonary Atelectasis; Quinazolines; Rupture, Spontaneous; Solitary Pulmonary Nodule; Tomography, X-Ray Computed

2013
Estrogen adversely affects the prognosis of patients with lung adenocarcinoma.
    Cancer science, 2015, Volume: 106, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; ErbB Receptors; Estradiol; Estrogen Receptor beta; Estrogens; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; MAP Kinase Signaling System; Middle Aged; Osteopontin; Pleural Effusion, Malignant; Prognosis; Prospective Studies; Quinazolines; Transcriptional Activation

2015
Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
    Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:1

    Topics: Adult; Aged; Antibodies, Monoclonal; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; DNA; ErbB Receptors; Exons; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Pleural Effusion, Malignant; Polymerase Chain Reaction; Quinazolines; Recurrence; Sensitivity and Specificity; Sequence Deletion

2011
Malignant pleural effusion from lung adenocarcinoma treated by gefitinib.
    Internal medicine (Tokyo, Japan), 2011, Volume: 50, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Apoptosis; Drainage; Gefitinib; Humans; Lung Neoplasms; Male; Pleural Effusion, Malignant; Quinazolines; Treatment Outcome

2011
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
    The European respiratory journal, 2012, Volume: 39, Issue:3

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Quinazolines; RNA

2012
Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failure.
    Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:2

    Topics: Adenocarcinoma; Adult; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphangitis; Lymphatic Metastasis; Neoplasm Staging; Pleural Effusion, Malignant; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Third; Quinazolines; Remission Induction; Respiratory Insufficiency; Sequence Deletion; Term Birth

2011
EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Cell Cycle Proteins; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microtubule-Associated Proteins; Middle Aged; Multivariate Analysis; Mutation Rate; Oncogene Proteins, Fusion; Pleural Effusion, Malignant; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Smoking; Translocation, Genetic

2012
Survival of lung adenocarcinoma patients with malignant pleural effusion.
    The European respiratory journal, 2013, Volume: 41, Issue:6

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Prospective Studies; Quinazolines; Sequence Analysis, DNA; Time Factors; Treatment Outcome

2013
EGFR mutations in malignant pleural effusion of non-small cell lung cancer: a case report.
    Lung cancer (Amsterdam, Netherlands), 2005, Volume: 49, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Polymerase Chain Reaction; Positron-Emission Tomography; Quinazolines; Treatment Outcome

2005
ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.
    Oncology research, 2006, Volume: 16, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Piperidines; Pleural Effusion, Malignant; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor Receptor-2

2006
Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer.
    International journal of cancer, 2006, Nov-15, Volume: 119, Issue:10

    Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; ErbB Receptors; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Mutation; Pleural Effusion, Malignant; Polymerase Chain Reaction; Predictive Value of Tests; Quinazolines; Treatment Outcome

2006
EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
    British journal of cancer, 2006, Nov-20, Volume: 95, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Polymerase Chain Reaction; Prognosis; Quinazolines; Sensitivity and Specificity; Treatment Outcome

2006
EGFR mutation status in pleural fluid predicts tumor responsiveness and resistance to gefitinib.
    Lung cancer (Amsterdam, Netherlands), 2007, Volume: 56, Issue:3

    Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Mutation; Pleural Effusion, Malignant; Polymerase Chain Reaction; Prognosis; Quinazolines; Tomography, X-Ray Computed

2007